BioAge Labs, Inc. (BIOA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for BioAge Labs, Inc. (BIOA:NASDAQ), powered by AI.

Current Price
$18.04
Sector
Healthcare
What is the BioAge Labs, Inc. stock price forecast?

BioAge Labs, Inc. is currently trading at $18.04. View real-time AI analysis on Alpha Lenz.

What is BioAge Labs, Inc. insider trading activity?

View the latest insider trading data for BioAge Labs, Inc. on Alpha Lenz.

What is BioAge Labs, Inc.'s P/E ratio?

View BioAge Labs, Inc.'s valuation metrics on Alpha Lenz.

BioAge Labs, Inc.

NASDAQ · BIOA
$18.04+1.59(+9.67%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about BioAge Labs, Inc.'s future dividend policy...
Alpha Chat Insight

BioAge Labs, Inc.'s ROE is -27.1%. Explore profitability and growth together.

Ask for details

Company Overview

BioAge Labs Inc. is a biotechnology company focused on discovering and developing therapies that can enhance the human lifespan and address age-related diseases. By leveraging advanced technologies like artificial intelligence and genomics, BioAge Labs aims to pinpoint key molecular drivers of aging. Its approach involves identifying biological pathways that extend healthy lifespan, then discovering compounds that can influence these pathways to develop innovative treatments for age-associated conditions such as cancer, cardiovascular diseases, and metabolic disorders. BioAge Labs conducts research that spans various stages, from preclinical studies to early-stage clinical trials, frequently collaborating with leading scientific institutions and pharmaceutical partners. Operating within the biopharmaceutical industry, the company's work significantly impacts healthcare and wellness sectors by potentially altering age-related disease progression and improving quality of life for aging populations. As part of the burgeoning field of biotechnology focusing on longevity, BioAge Labs holds a notable place in the financial market by engaging in an area of medicine that combines cutting-edge bioinformatics with traditional biopharmaceutical research and development.

CEODr. Kristen Fortney Ph.D.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees62

Company Statistics

FY 2025

Profile

N/AMarket Cap
$8.99MRevenue
0.00Shares Out
62Employees

Margins

N/AGross
-883.61%EBITDA
-1031.46%Operating
-896.11%Pre-Tax
-896.11%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-24.68%ROA
-27.09%ROE
-24.47%ROIC

Financial Health

$188.89MCash & Cash Equivalents
$-166.05MNet Debt
8.39%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

BioAge Labs, Inc. (ticker: BIOA) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 62 employees.

The current price is $18.04 with a P/E ratio of -x and P/B of -x.

ROE is -27.09% and operating margin is -1031.46%. Annual revenue is $9M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
BioAge Labs, Inc. (BIOA) Stock Forecast 2026 $18.04 — Price, Financials & Analyst Targets | Alpha Lenz